NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CAR-T 細胞療法的全球市場:產品類型、腫瘤類型、適應症、治療類型、目標抗原、最終用戶、區域競爭/預測/機會(2026)

Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition Forecast & Opportunities, 2026

出版商 TechSci Research 商品編碼 1024097
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

CAR-T 細胞療法的全球市場:產品類型、腫瘤類型、適應症、治療類型、目標抗原、最終用戶、區域競爭/預測/機會(2026) Global CAR-T Cell Therapy Market, By Product Type, By Tumor Type, By Indication, By Treatment Type, By Targeted Antigen, By End User, By Region, Competition Forecast & Opportunities, 2026
出版日期: 2021年08月01日內容資訊: 英文 115 Pages
簡介

到2026年,全球CAR-T細胞治療市場預計將達到61.3456億美元,預測期內復合年增長率為33.11%。這個市場的增長是由於癌症患病率的增加和對替代療法無反應的病例數量的增加。增加臨床試驗和開發新的有效療法也是 CAR-T 細胞療法市場的關鍵增長因素。此外,預計到 2026 年,對突破性療法的需求不斷增長以及 CAR-T 細胞療法對癌症治療的有效性將推動市場增長。

此外,免疫腫瘤學領域的繁榮和研發支出的增加預計將對全球CAR-T細胞治療市場的增長產生積極影響。然而,全球CAR-T細胞治療市場也可能面臨一些挑戰。 CAR-T 細胞療法的副作用會導致神經病變和細胞因子釋放綜合徵 (CRS),從而阻礙市場增長。另一個問題是,由於CAR-T細胞製造工藝複雜,治療成本高。

本報告調查了全球CAR-T細胞治療市場,包括市場概況、產品類型、腫瘤類型、適應症、治療類型、靶標抗原、最終用戶、區域市場規模趨勢和預測、市場趨勢,總結了增長因素、市場機會、競爭條件、主要公司的簡介等。

目錄

第 1 章產品概述

第 2 章調查方法

第 3 章新型冠狀病毒感染 (COVID-19) 對 CAR-T 細胞治療市場的影響

第 4 章執行摘要

第 5 章客戶反饋

  • 品牌知名度
  • 未滿足的需求和挑戰
  • 推動 CAR-T 細胞治療市場的因素

第六章全球 CAR-T 細胞療法市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 產品類型
      • Yescarta (Axicabtagene Cilouleucel)
      • Kymriah (Tisagenlecleucel)
      • Tecartus (brexucabtagene autoleucel)
      • Breyanzi (lisocabtagene maraleucel)
      • Abecma (idecabtagene vicleucel)
      • 其他
    • 按腫瘤類型
      • 血液腫瘤
      • 實體瘤
    • 適應症
      • 瀰漫性大 B 細胞淋巴瘤 (DLBCL)
      • 急性淋巴細胞白血病 (ALL)
      • 濾泡性淋巴瘤 (FL)
      • 套細胞淋巴瘤 (MCL)
      • 其他
    • 按治療類型
      • 單次處理
      • 組合處理
    • 按目標抗原
      • CD 19
      • BCMA(B細胞成熟抗原)
      • 其他
    • 最終用戶
      • 醫院
      • 專科診所
      • 門診手術中心
      • 其他
    • 按公司
    • 按地區
  • 產品市場地圖

第 7 章北美 CAR-T 細胞療法市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 按產品類型
    • 按腫瘤類型
    • 按指示
    • 按治療類型
    • 按目標抗原
    • 最終用戶
    • 按國家/地區
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章歐洲 CAR-T 細胞療法市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 按產品類型
    • 按腫瘤類型
    • 按指示
    • 按治療類型
    • 按目標抗原
    • 最終用戶
    • 按國家/地區
  • 歐洲:國家分析
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙

第 9 章亞太地區CAR-T細胞治療市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 按產品類型
    • 按腫瘤類型
    • 按指示
    • 按治療類型
    • 按目標抗原
    • 最終用戶
    • 按國家/地區
  • 亞太地區:國家分析
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞

第 10 章南美CAR-T細胞治療市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 按產品類型
    • 按腫瘤類型
    • 按指示
    • 按治療類型
    • 按目標抗原
    • 最終用戶
    • 按國家/地區
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲CAR-T細胞治療市場展望

  • 市場規模和預測
  • 市場份額及預測
    • 按產品類型
    • 按腫瘤類型
    • 按指示
    • 按治療類型
    • 按目標抗原
    • 最終用戶
    • 按國家/地區
  • 中東/非洲:國家分析
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國

第 12 章市場動態

  • 促進因素
  • 挑戰

第 13 章市場趨勢

第14章競爭形勢

  • 競爭前景
  • 主要公司
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Co.
    • Cellectis SA
    • Amgen Inc.
    • Pfizer Inc.
    • Merck & Co. Inc.
    • Intellia Therapeutics Inc.
    • Novartis AG
    • Poseida Therapeutics Inc.
    • Johnson & Johnson SA
    • Allogene Therapeutics Inc.
    • Autolus Therapeutics PLC
    • Humanigen Inc
    • Sangamo Therapeutics, Inc.

第 15 章戰略建議

第 16 章關於我們和免責聲明

目錄
Product Code: 5168

Global CAR-T cell therapy market is expected to reach USD6134.56 million by 2026, growing at a CAGR of 33.11% over the forecast period. The growth in the market can be attributed to increasing prevalence of cancer and growing pool of patients who are showing response failure towards alternative treatments. Rising clinical trials and development of new and effective therapy options is also acting as key growth driver for global CAR-T cell therapy market. In addition to this, growing need for breakthrough therapeutic solutions and effectiveness of CAR-T cell therapy in treating cancer are expected to fuel the market growth through 2026.

Moreover, thriving immuno-oncology sector and increasing R&D expenditure are expected to positively influence the growth of global CAR-T cell therapy market. However, global CAR-T cell therapy market might also face some challenges. The side effects of CAR-T cell therapy may lead to neurological problems and cytokine release syndrome (CRS), which might hamper the market growth. Also, the complicated manufacturing process of CAR-T cells makes it a costly treatment.

Global CAR-T cell therapy market can be segmented based on product type, tumor type, indication, treatment type, targeted antigen, end user, company and region. Based on indication, the market can be segmented into Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle cell lymphoma (MCL) and others. Among them, Acute Lymphoblastic Leukemia (ALL) segment is expected to witness the fastest CAGR during the forecast period owing to its high prevalence around the globe.

Regionally, North America dominated the global CAR-T cell therapy market in 2020 and is further expected to hold its dominance during the forecast period owing to increasing development and launch of new therapies for the treatment of cancer by key healthcare and drug manufacturers in the region. Further, Europe is expected to be the second largest market for global CAR-T cell therapy through 2026 as the region is witnessing extensive research for development of cancer treatment therapies.

Major companies operating in global CAR-T cell therapy market include Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Co., Cellectis SA, Amgen Inc., Pfizer Inc., Merck & Co. Inc., Intellia Therapeutics Inc., Novartis AG, Poseida Therapeutics Inc., Johnson & Johnson SA, Allogene Therapeutics Inc., Autolus Therapeutics PLC, Humanigen Inc., Sangamo Therapeutics, Inc., among others. The market players are investing on extensive research & development activities to launch new CAR-T Cell therapies to strengthen their positions in global market.

Years considered for this report:

  • Historical Years: 2017-2019
  • Base Year: 2020
  • Estimated Year: 2021E
  • Forecast Period: 2022F-2026F

Objective of the Study:

  • To analyze the historical growth in the market size of global CAR-T cell therapy market from 2017 to 2020.
  • To estimate and forecast the market size of global CAR-T Cell Therapy market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global CAR-T Cell Therapy market based on product type, tumor type, indication, treatment type, by targeted antigen, by end user, company and regional distribution.
  • To identify drivers and challenges for global CAR-T cell therapy market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global CAR-T cell therapy market.
  • To identify and analyze the profile of leading players operating in the global CAR-T cell therapy market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of CAR-T cell therapy companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated the global CAR-T cell therapy market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • CAR-T cell therapy drug manufacturers/ companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to CAR-T cell therapy
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as CAR-T cell therapy drug manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global CAR-T cell therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global CAR-T Cell Therapy Market, By Product Type:

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Abecma (idecabtagene vicleucel)
  • Others

Global CAR-T Cell Therapy Market, By Tumor Type

  • Hematological Malignancies
  • Solid Tumors

Global CAR-T Cell Therapy Market, By Indication:

  • Diffused Large B-cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma (FL)
  • Mantle Cell Lymphoma (MCL)
  • Others

Global CAR-T Cell Therapy Market, By Treatment Type

  • Single Treatment
  • Combination Treatment

Global CAR-T Cell Therapy Market, By Targeted Antigen:

  • CD 19
  • BCMA (B-Cell Maturation Antigen)
  • Others

Global CAR-T Cell Therapy Market, By End User:

  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Others

Global CAR-T Cell Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global CAR-T cell therapy market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global CAR-T Cell Therapy Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Unmet Need and Challenges
  • 5.3. Factors Driving the CAR-T Cell Therapy Market

6. Global CAR-T Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), Others)
    • 6.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
    • 6.2.3. By Indication (Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
    • 6.2.4. By Treatment Type (Single Treatment, Combination Treatment)
    • 6.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
    • 6.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 6.2.7. By Company (2020)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. North America CAR-T Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tumor Type
    • 7.2.2. By Indication
    • 7.2.3. By Treatment Type
    • 7.2.4. By Targeted Antigen
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States CAR-T Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tumor Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Treatment Type
        • 7.3.1.2.4. By Targeted Antigen
        • 7.3.1.2.5. By End User
    • 7.3.2. Canada CAR-T Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tumor Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Treatment Type
        • 7.3.2.2.4. By Targeted Antigen
        • 7.3.2.2.5. By End User
    • 7.3.3. Mexico CAR-T Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tumor Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Treatment Type
        • 7.3.3.2.4. By Targeted Antigen
        • 7.3.3.2.5. By End User

8. Europe CAR-T Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tumor Type
    • 8.2.2. By Indication
    • 8.2.3. By Treatment Type
    • 8.2.4. By Targeted Antigen
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany CAR-T Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tumor Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Treatment Type
        • 8.3.1.2.4. By Targeted Antigen
        • 8.3.1.2.5. By End User
    • 8.3.2. France CAR-T Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tumor Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Treatment Type
        • 8.3.2.2.4. By Targeted Antigen
        • 8.3.2.2.5. By End User
    • 8.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tumor Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Treatment Type
        • 8.3.3.2.4. By Targeted Antigen
        • 8.3.3.2.5. By End User
    • 8.3.4. Italy CAR-T Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Tumor Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Treatment Type
        • 8.3.4.2.4. By Targeted Antigen
        • 8.3.4.2.5. By End User
    • 8.3.5. Spain CAR-T Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Tumor Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Treatment Type
        • 8.3.5.2.4. By Targeted Antigen
        • 8.3.5.2.5. By End User

9. Asia-Pacific CAR-T Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tumor Type
    • 9.2.2. By Indication
    • 9.2.3. By Treatment Type
    • 9.2.4. By Targeted Antigen
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. Japan CAR-T Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tumor Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Treatment Type
        • 9.3.1.2.4. By Targeted Antigen
        • 9.3.1.2.5. By End User
    • 9.3.2. China CAR-T Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tumor Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Treatment Type
        • 9.3.2.2.4. By Targeted Antigen
        • 9.3.2.2.5. By End User
    • 9.3.3. India CAR-T Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tumor Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Treatment Type
        • 9.3.3.2.4. By Targeted Antigen
        • 9.3.3.2.5. By End User
    • 9.3.4. South Korea CAR-T Cell Therapy Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Tumor Type
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Treatment Type
        • 9.3.4.2.4. By Targeted Antigen
        • 9.3.4.2.5. By End User
    • 9.3.5. Australia CAR-T Cell Therapy Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Tumor Type
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Treatment Type
        • 9.3.5.2.4. By Targeted Antigen
        • 9.3.5.2.5. By End User

10. South America CAR-T Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tumor Type
    • 10.2.2. By Indication
    • 10.2.3. By Treatment Type
    • 10.2.4. By Targeted Antigen
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil CAR-T Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tumor Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Treatment Type
        • 10.3.1.2.4. By Targeted Antigen
        • 10.3.1.2.5. By End User
    • 10.3.2. Argentina CAR-T Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tumor Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Treatment Type
        • 10.3.2.2.4. By Targeted Antigen
        • 10.3.2.2.5. By End User
    • 10.3.3. Colombia CAR-T Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tumor Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Treatment Type
        • 10.3.3.2.4. By Targeted Antigen
        • 10.3.3.2.5. By End User

11. Middle East and Africa CAR-T Cell Therapy Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Tumor Type
    • 11.2.2. By Indication
    • 11.2.3. By Treatment Type
    • 11.2.4. By Targeted Antigen
    • 11.2.5. By End User
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa CAR-T Cell Therapy Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Tumor Type
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Treatment Type
        • 11.3.1.2.4. By Targeted Antigen
        • 11.3.1.2.5. By End User
    • 11.3.2. Saudi Arabia CAR-T Cell Therapy Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Tumor Type
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Treatment Type
        • 11.3.2.2.4. By Targeted Antigen
        • 11.3.2.2.5. By End User
    • 11.3.3. UAE CAR-T Cell Therapy Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Tumor Type
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Treatment Type
        • 11.3.3.2.4. By Targeted Antigen
        • 11.3.3.2.5. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Gilead Sciences Inc.
    • 14.2.2. AbbVie Inc.
    • 14.2.3. Bristol Myers Squibb Co.
    • 14.2.4. Cellectis SA
    • 14.2.5. Amgen Inc.
    • 14.2.6. Pfizer Inc.
    • 14.2.7. Merck & Co. Inc.
    • 14.2.8. Intellia Therapeutics Inc.
    • 14.2.9. Novartis AG
    • 14.2.10. Poseida Therapeutics Inc.
    • 14.2.11. Johnson & Johnson SA
    • 14.2.12. Allogene Therapeutics Inc.
    • 14.2.13. Autolus Therapeutics PLC
    • 14.2.14. Humanigen Inc
    • 14.2.15. Sangamo Therapeutics, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Figures

  • Figure 1: Global CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 2: Global CAR-T Cell Therapy Market Share, By Product Type, By Value, , 2017-2026F
  • Figure 3: Global CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 4: Global CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 5: Global CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 6: Global CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 7: Global CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 8: Global CAR-T Cell Therapy Market Share, By Company, By Value, 2020
  • Figure 9: Global CAR-T Cell Therapy Market Share, By Region, By Value, 2017-2026F
  • Figure 10: Global CAR-T Cell Therapy Product Market Map, By Value, 2017-2026F
  • Figure 11: North America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 12: North America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 13: North America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 14: North America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 15: North America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 16: North America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 17: North America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
  • Figure 18: United States CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 19: United States CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 20: United States CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 21: United States CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 22: United States CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 23: United States CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 24: Canada CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 25: Canada CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 26: Canada CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 27: Canada CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 28: Canada CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 29: Canada CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 30: Mexico CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 31: Mexico CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 32: Mexico CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 33: Mexico CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 34: Mexico CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 35: Mexico CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 36: Europe CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 37: Europe CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 38: Europe CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 39: Europe CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 40: Europe CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 41: Europe CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 42: Europe CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
  • Figure 43: Germany CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 44: Germany CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 45: Germany CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 46: Germany CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 47: Germany CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 48: Germany CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 49: France CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 50: France CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 51: France CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 52: France CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 53: France CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 54: France CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 55: United Kingdom CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 56: United Kingdom CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 57: United Kingdom CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 58: United Kingdom CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 59: United Kingdom CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 60: United Kingdom CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 61: Italy CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 62: Italy CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 63: Italy CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 64: Italy CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 65: Italy CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 66: Italy CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 67: Spain CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 68: Spain CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 69: Spain CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 70: Spain CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 71: Spain CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 72: Spain CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 73: Asia-Pacific CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 74: Asia-Pacific CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 75: Asia-Pacific CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 76: Asia-Pacific CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 77: Asia-Pacific CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 78: Asia-Pacific CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 79: Asia-Pacific CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
  • Figure 80: Japan CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 81: Japan CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 82: Japan CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 83: Japan CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 84: Japan CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 85: Japan CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 86: China CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 87: China CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 88: China CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 89: China CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 90: China CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 91: China CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 92: India CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 93: India CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 94: India CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 95: India CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 96: India CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 97: India CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 98: South Korea CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 99: South Korea CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 100: South Korea CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 101: South Korea CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 102: South Korea CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 103: South Korea CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 104: Australia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 105: Australia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 106: Australia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 107: Australia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 108: Australia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 109: Australia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 110: South America CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 111: South America CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 112: South America CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 113: South America CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 114: South America CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 115: South America CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 116: South America CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
  • Figure 117: Brazil CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 118: Brazil CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 119: Brazil CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 120: Brazil CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 121: Brazil CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 122: Brazil CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 123: Argentina CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 124: Argentina CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 125: Argentina CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 126: Argentina CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 127: Argentina CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 128: Argentina CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 129: Colombia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 130: Colombia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 131: Colombia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 132: Colombia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 133: Colombia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 134: Colombia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 135: Middle East and Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 136: Middle East and Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 137: Middle East and Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 138: Middle East and Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 139: Middle East and Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 140: Middle East and Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 141: Middle East and Africa CAR-T Cell Therapy Market Share, By Country, By Value, 2017-2026F
  • Figure 142: South Africa CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 143: South Africa CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 144: South Africa CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 145: South Africa CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 146: South Africa CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 147: South Africa CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 148: Saudi Arabia CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 149: Saudi Arabia CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 150: Saudi Arabia CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 151: Saudi Arabia CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 152: Saudi Arabia CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 153: Saudi Arabia CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F
  • Figure 154: UAE CAR-T Cell Therapy Market Size, By Value (USD Million), 2017-2026F
  • Figure 155: UAE CAR-T Cell Therapy Market Share, By Tumor Type, By Value, 2017-2026F
  • Figure 156: UAE CAR-T Cell Therapy Market Share, By Indication, By Value, 2017-2026F
  • Figure 157: UAE CAR-T Cell Therapy Market Share, By Treatment Type, By Value, 2017-2026F
  • Figure 158: UAE CAR-T Cell Therapy Market Share, By Targeted Antigen, By Value, 2017-2026F
  • Figure 159: UAE CAR-T Cell Therapy Market Share, By End User, By Value, 2017-2026F